{"filings":[{"id":1195956,"accession_number":"0001140361-26-025971","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2026-06-22T20:34:55+00:00","items":["5.07"],"status":"ready","headline":"Balchem shareholders elect directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Fischer and Daniel Knutson elected as Class 3 directors with 25.3M and 26.8M votes for, respectively.","Ratification of RSM US LLP as independent auditor for FY 2026 passed with 28.7M votes for, 457k against.","Advisory approval of named executive officer compensation passed with 26.6M votes for, 554k against.","All proposals passed by wide margins; no material changes to board or governance structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99874,"accession_number":"0000009326-26-000016","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.","Adjusted EBITDA $74.3M (+12.1%); free cash flow $33.8M; operating cash flow $40.1M.","All three segments posted sales and earnings growth; record Q1 net sales, EBITDA, and net earnings.","New clinical fMRI study on VitaCholine suggests cognitive health benefits in post-menopausal women.","CEO cites strong business model resilience; no guidance change despite geopolitical and trade uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":270709000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116150,"accession_number":"0000009326-26-000004","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem reports record Q4 net sales $263.6M, adjusted EPS $1.31; full year revenue tops $1B for first time","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $263.6M (+9.8% YoY); GAAP EPS $1.21 vs $1.03; adjusted EPS $1.31 vs $1.13.","Full year revenue $1.037B (record, +8.8%); GAAP net earnings $154.8M (+20.5%); adjusted EBITDA $274.9M (+9.8%).","Record free cash flow $173.6M; CEO cites double-digit dividend increase for 2025.","All three segments delivered sales and earnings growth in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":4.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":1037161000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116149,"accession_number":"0001140361-26-006184","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Balchem appoints Erin L. Gilson as CAO effective April 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William A. Backus, VP and Chief Accounting Officer, retiring on March 31, 2026.","Erin L. Gilson elected VP and Chief Accounting Officer, effective April 1, 2026.","Gilson joined Balchem in February 2016; currently Senior Director, Accounting and Financial Reporting.","No material changes to Gilson's compensatory arrangement as a result of the election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132591,"accession_number":"0001140361-25-045137","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Balchem declares $0.96 annual dividend (10.3% increase), authorizes repurchase of up to 4M shares","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.96 per share declared on Dec 9, 2025, payable Jan 20, 2026 to holders of record Dec 23, 2025.","10.3% increase over prior year annual dividend, marking the 17th consecutive annual increase.","New stock repurchase program authorizes up to 4 million shares, replacing prior program with no expiration date.","Repurchases may be made in open market or private transactions at management's discretion, with no obligation to acquire any specific amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132590,"accession_number":"0000009326-25-000019","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q3 2025: record sales $267.6M, adj. EPS $1.35, all segments grow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales $267.6M (+11.5% YoY); GAAP EPS $1.24 vs $1.03; adjusted EPS $1.35 vs $1.13.","Record adjusted EBITDA $71.4M (+11.0% YoY); free cash flow $50.7M.","All three segments achieved sales and earnings growth; new NY microencapsulation plant to double capacity.","Net debt reduced to $88.9M, leverage 0.3x; repaid $36M on revolver during Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":3.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":773544000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149122,"accession_number":"0000009326-25-000012","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q2 2025: record net sales $255.5M, adj. EPS $1.27 beat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $255.5M, +9.1% YoY; GAAP EPS $1.17 vs $0.98 prior year quarter.","Record adjusted EBITDA $69.2M (+11.2%); adjusted EPS $1.27 vs $1.09.","All three segments grew; record sales and earnings in Human Nutrition & Health and Specialty Products.","Plans new $36M micro-encapsulation facility in Orange County, NY, pending county approval.","EU imposes provisional anti-dumping duties of 95.4%-120.8% on Chinese choline chloride imports effective July 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":505986000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168118,"accession_number":"0001140361-25-023176","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Balchem shareholders elect three Class 1 directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Theodore L. Harris elected with 24.96M votes for; 1.26M against; 963k abstain; 2.20M broker non-votes.","Monica Vicente elected with 26.45M for; 718k against; 18k abstain; 2.20M broker non-votes.","Matthew Wineinger elected with 26.13M for; 1.04M against; 19k abstain; 2.20M broker non-votes.","RSM US LLP ratified as auditor for FY2025: 28.86M for, 522k against, 8k abstain.","Advisory approval of executive compensation passed: 25.45M for, 1.69M against, 49k abstain; 2.20M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168117,"accession_number":"0001628280-25-019487","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q1 net sales $250.5M record; adj. EPS $1.22 vs $1.03 YoY; all segments grow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $250.5M, up 4.5% YoY; GAAP EPS $1.13 vs $0.89; adjusted EPS $1.22 vs $1.03.","Record adjusted EBITDA of $66.3M, up 8.9% YoY; net earnings $37.1M, up 27.8%.","All three segments (Human Nutrition, Animal Nutrition, Specialty Products) posted sales and earnings growth.","Operating cash flow $36.5M; free cash flow $31.0M in Q1 2025.","Launched new corporate website and product brand sites; released 2024 Sustainability Report on April 22."],"consensus_eps_estimate":null,"consensus_eps_actual":1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":250519000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185325,"accession_number":"0001140361-25-006756","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Balchem CAO William A. Backus to retire on March 31, 2026; successor not yet named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William A. Backus, Vice President and Chief Accounting Officer, notified of retirement effective March 31, 2026.","No material changes to Backus' compensatory arrangement as a result of planned retirement.","Successor will be announced at a later date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185324,"accession_number":"0001628280-25-006975","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q4 record net sales $240M, adjusted EBITDA $62.8M, EPS $1.03","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales record $240.0M (+4.9% YoY); GAAP EPS $1.03 vs $0.82; adjusted EPS $1.13 vs $0.95.","Q4 adjusted EBITDA record $62.8M (+13.4%); free cash flow $39.8M.","Full-year record net sales $953.7M (+3.4%); GAAP EPS $3.93 vs $3.35; adjusted EPS $4.37 vs $4.00.","Full-year adjusted EBITDA record $250.3M (+8.4%); operating cash flow $182.0M.","Dividend increased double-digits; debt reduced by $119.6M in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":3.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":953684000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185323,"accession_number":"0001140361-25-004806","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Balchem adopts executive severance policy and enhances deferred comp match for officers","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["New Executive Severance Policy provides cash severance (multiple of salary plus target bonus) and COBRA for termination without Cause or Involuntary Termination within Change in Control (CIC) Period.","Outside CIC: cash paid in installments over Severance Period; equity treated per award terms. Within CIC: equity accelerates fully (time-based) and performance at target.","Company will match executive contributions to deferred compensation plan up to 6% of base salary, matching the 401(k) plan percentage.","Severance conditioned on signing a separation agreement with restrictive covenants including non-compete and non-solicit.","Policy effective February 12, 2025; Committee retains authority to interpret and amend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201906,"accession_number":"0001140361-24-048915","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Balchem declares $0.87 dividend, 10.1% increase; payable Jan 17, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend set at $0.87 per share, a 10.1% increase versus prior year.","Payable January 17, 2025 to holders of record December 26, 2024.","This marks the 16th consecutive annual dividend increase.","CEO Ted Harris cites strong financial performance and Board confidence in long-term strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201905,"accession_number":"0001628280-24-043760","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q3 net sales up 4.3% to $239.9M; record adjusted EBITDA $64.4M, up 7.6% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $1.03 versus $0.90 prior year; adjusted EPS record $1.13 versus $1.04.","Human Nutrition & Health and Specialty Products segments drove strong sales and earnings growth.","Cash from operations $51.3M; free cash flow $42.2M; repaid $39.6M revolving debt, net debt $153.3M (0.6x leverage).","Launched K2Vital Delta Fermented, VitaCholine Pro-Flo, and AminoShure-XL during the quarter.","Year-to-date 2024 net earnings $94.9M vs $81.9M; net sales $713.7M vs $693.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":713680000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201904,"accession_number":"0001140361-24-043626","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Joyce Lee resigns from Balchem board following planned employment change","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joyce Lee resigned as director on Oct 16, 2024, due to planned change in principal employment.","Board accepted resignation; served for five years.","No replacement announced; Board expressed appreciation for service.","Resignation under corporate governance guidelines for employment change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217946,"accession_number":"0001140361-24-041566","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Balchem reclasses four directors to balance board classes; adopts MGCL 3-804(c) vacancy-filling provision","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Knutson, Lee, Vicente, and Fish moved among Class 1, 2, and 3 to approximate one-third per class, effective Sept 20, 2024.","Board now has three Class 1 (term exp. 2025), two Class 2 (2027), three Class 3 (2026) directors.","Board adopted resolution to be subject to MGCL 3-804(c); vacancies may be filled only by majority of remaining directors.","Articles Supplementary filed with Maryland SDAT on Sept 19, 2024, reflecting the election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217945,"accession_number":"0001628280-24-033055","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.","Record adjusted EBITDA $62.3M (+5.0% YoY); cash from ops $45.0M; free cash flow $38.4M.","Human Nutrition & Health and Specialty Products segments post strong sales and earnings growth.","Launched Optifolin+ patented choline-enriched folate ingredient on May 20, 2024.","Repaid $35M revolving debt; net debt $202.8M; leverage ratio 0.9x."],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":473740000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237877,"accession_number":"0001140361-24-031096","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Balchem shareholders elect four Class 2 directors and ratify RSM US LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel Knutson, Joyce Lee, Olivier Rigaud, Monica Vicente elected as Class 2 directors (2027 term).","Joyce Lee received 23,968,891 votes for vs 3,987,153 against; others passed with >85% support.","Appointment of RSM US LLP ratified with 28,981,040 votes for, 536,045 against.","Say-on-pay advisory approved with 27,117,930 votes for (96.9% of shares voted).","All results from June 20, 2024 Annual Meeting; broker non-votes reported for director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237876,"accession_number":"0001628280-24-020128","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem reports record Q1 net sales of $239.7M, adjusted EBITDA up 8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $239.7M (+3.1% YoY), adjusted EBITDA $60.9M (+8.0% YoY), both all-time records.","GAAP EPS $0.89 vs $0.70; adjusted EPS $1.03 vs $0.94 in prior-year quarter.","Human Nutrition & Health segment sales $152.7M (+15.1%), earnings $33.3M (+80.4%).","Cash from operations $33.4M; free cash flow $26.8M for Q1 2024.","VitaCholine became Proud Partner of New York Jets, first sponsorship in nutritional ingredient category."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":239659000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255368,"accession_number":"0001140361-24-016602","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Balchem announces role changes: Griffin to Corporate Development, Bengtsson adds Animal Nutrition oversight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan H. Griffin moves from SVP & GM, Animal Nutrition & Health to SVP, Corporate Development, effective immediately.","C. Martin Bengtsson, EVP & CFO, expands responsibilities to include leadership of Animal Nutrition & Health segment.","No material changes to compensatory arrangements for either officer as a result of these changes.","Effective date of both changes: March 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255367,"accession_number":"0001628280-24-005203","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q4 adj. EBITDA up 5.4% to $55.4M; free cash flow $56M, record Human Nutrition sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.82 vs $0.66 prior year; adjusted EPS $0.95 vs $0.94.","Full year adjusted EBITDA $230.9M (+7.1%); record free cash flow $151.1M.","Human Nutrition & Health Q4 sales $138M (+5.8%) record; earnings from ops up 43.8%.","Dividend increased double-digit; $25.4M returned to shareholders in 2023.","CEO expects both top and bottom line growth for full year 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":3.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":922439000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272837,"accession_number":"0001140361-23-056364","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Balchem raises annual dividend 11.3% to $0.79/share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board declared $0.79 per share dividend, an 11.3% increase over prior year.","Payable January 19, 2024 to holders of record December 27, 2023.","Marks the 15th consecutive annual dividend increase; CEO cites confidence in long-term strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272836,"accession_number":"0001628280-23-035357","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q3 sales down 5.9% to $229.9M, but EPS up to $0.90; record adjusted EBITDA $59.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.90 vs $0.78 prior year; adjusted EPS $1.04 vs $1.00.","Record quarterly adjusted EBITDA $59.9M, up 11.4% from $53.8M YoY.","Cash from ops $46.5M, free cash flow $38.2M; net debt reduced by $25M to $303.6M.","New board members: Olivier Rigaud (Corbion CEO) & Monica Vicente (Fresh Del Monte CFO) elected Sept 6.","Management: demand volatile, not yet normalized, but company well-positioned for recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":693740000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289685,"accession_number":"0001140361-23-042673","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Balchem elects Olivier Rigaud and Monica Vicente to Board effective Sept 6, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Olivier Rigaud, CEO of Corbion N.V., and Monica Vicente, CFO of Fresh Del Monte Produce Inc., join Balchem's Board as Class 2 directors.","Both directors are independent and qualify as audit committee financial experts under SEC rules.","Rigaud appointed to Audit and Governance committees; Vicente appointed to Audit committee.","Directors will stand for election at the 2024 Annual Meeting, participating in non-employee director compensation program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289684,"accession_number":"0001628280-23-026002","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q2 sales $231.3M (-2.3% YoY); adjusted EPS $1.06; record EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $231.3M, down 2.3% YoY; GAAP net earnings $30.1M ($0.93 EPS).","Record quarterly adjusted EBITDA $59.1M, up 4.6% YoY; adjusted EPS $1.06 (vs $1.07 prior year).","Operating cash flow $35.0M; free cash flow $31.7M; repaid $26M revolving debt, net debt $338.7M.","Leverage ratio 1.5x net debt; completed new Vitacholine manufacturing unit for choline production.","Effective tax rate declined to 21.6% from 24.1% (255 bps lower)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":463792000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310550,"accession_number":"0001140361-23-031415","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Balchem shareholders approve Amended 2017 Omnibus Incentive Plan, adding 800,000 authorized shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting held June 22, 2023; Plan approved with 26,513,603 votes for (96.1% of votes cast).","David Fischer elected Class 3 director with 22,999,214 votes for.","RSM US LLP ratified as independent auditor (28,779,713 for).","Advisory say-on-pay approved; Company will hold vote every year based on shareholder preference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310549,"accession_number":"0001628280-23-013743","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem reports record Q1 sales of $232.5M; net earnings down 21.5% to $22.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 net sales of $232.5M (+1.6% YoY); gross margin $73.2M.","GAAP net earnings $22.7M ($0.70 EPS), down 21.5% from prior year $28.9M.","Adjusted EBITDA record $56.1M (+4.8% YoY); adjusted EPS $0.94 vs $1.03.","Cash from operations $34.8M, up 396% YoY; free cash flow $25.2M.","No guidance update; company cites challenging market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":232540000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329195,"accession_number":"0001628280-23-004959","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q4 net sales up 9.1% to $232.5M; adjusted EPS $0.94; dividend raised 10.9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $232.5M (+9.1% YoY); GAAP net earnings $21.4M (-14.2%); adjusted net earnings $30.3M (+9.1%).","Adjusted EBITDA $52.3M (+14.6%); full-year record sales $942.4M (+17.9%) with record sales in all three segments.","Full-year record GAAP EPS $3.25; record adjusted EPS $4.03; operating cash flow $138.5M; free cash flow $89.4M.","Dividend increased 10.9% to $0.71/share, marking 14th consecutive year of double-digit dividend growth.","Net debt $374.0M; leverage ratio 1.7x; repaid $103M revolving debt in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":3.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":942358000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346820,"accession_number":"0001140361-22-044725","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Balchem amends bylaws to enhance shareholder nomination procedures and require Rule 14a-19 compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended and restated Bylaws effective December 5, 2022.","Article II enhanced procedural mechanics for shareholder nominations and proxy solicitations.","New requirement to comply with SEC Rule 14a-19 for director nominations.","Also incorporated ministerial, clarifying and conforming changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346819,"accession_number":"0001140361-22-044587","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Balchem declares Q4 dividend $0.71/share, 10.9% increase; 14th consecutive annual raise","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.71 per share payable Jan 20, 2023 to holders of record Dec 27, 2022.","Represents a 10.9% increase over the prior year's annual dividend.","14th consecutive annual dividend increase; CEO cites consistent financial performance.","Board declared the dividend on December 5, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346818,"accession_number":"0001628280-22-028349","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q3 revenue up 23.4% to $244.3M; adjusted EPS $1.00 vs $0.92 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $244.3M (+23.4% YoY); GAAP EPS $0.78, adjusted EPS $1.00.","Adjusted EBITDA $53.8M (+11.2% YoY); net earnings $25.2M (+0.9%).","Completed Bergstrom (OptiMSM) acquisition on Aug 30, 2022, adding MSM capabilities.","Cash from ops $41.6M; free cash flow $26.8M; net debt $406.1M (leverage 1.9x)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":709827000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363196,"accession_number":"0001140361-22-035194","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Balchem SVP & GM James Hyde to retire upon successor appointment; transition through 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James C. Hyde, SVP and General Manager of Human Nutrition & Health, notified company of retirement.","He will step down when successor is appointed and stay for transition, retiring in 2023.","No material changes to Hyde's compensatory arrangement as a result of the planned retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363195,"accession_number":"0001140361-22-034013","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Balchem grants CEO Harris 130,000 options; $6.3M value for retention","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["130,000 stock options awarded to CEO Ted Harris with grant date Sep 15, 2022; fair value ~$6.3M.","Options split into four tranches at FMV and plus 10%/15%/20% premiums; vest over 5 years.","Bylaws amended to adopt majority voting for director elections, opt out of Maryland control share law.","Board size range confirmed at 3–15; CEO no longer required to be a director; indemnification updated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363191,"accession_number":"0001628280-22-024348","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K/A","filed_at":"2022-09-06T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Balchem files Kappa bioscience financials: 2021 revenue NOK 241M, net profit NOK 14.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kappa (Kechu Bidco) 2021: revenue NOK 240.9M, op. profit NOK 42.7M, net profit NOK 14.6M including NOK 26.7M discontinued ops loss.","Total assets NOK 1,059M, equity NOK 594M, borrowings NOK 245M, cash NOK 100M as of Dec 31, 2021.","Unaudited pro forma combined financials for FY2021 and H1 2022 also filed, reflecting acquisition.","Audit opinion qualified for omission of comparative info; prepared per IFRS for SEC Rule 3-05.","Discontinued ops loss of NOK 26.7M from Kappa Ingredients GmbH (deconsolidated Nov 2021)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363194,"accession_number":"0001140361-22-031509","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Balchem acquires Bergstrom Nutrition, maker of OptiMSM, for undisclosed sum","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Albion Laboratories, a Balchem subsidiary, acquired Cardinal Associates (Bergstrom Nutrition), a global leader in MSM manufacturing.","Bergstrom's OptiMSM brand is the only MSM with U.S. GRAS designation; complements Balchem's mineral products and health platforms.","Bergstrom Nutrition to be integrated into Balchem's Human Nutrition & Health segment under Minerals & Nutrients unit.","No financial terms of the acquisition were disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363193,"accession_number":"0001140361-22-027537","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Balchem enters $550M revolving credit facility, refinances existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $550M senior revolving credit facility matures in 5 years from July 27, 2022.","Proceeds used to refinance all outstanding indebtedness under the prior 2018 credit agreement.","Financial covenants: max consolidated net leverage ratio of 4.00x; min interest coverage of 3.00x.","Facility includes $10M letter of credit sublimit and $10M swing line sublimit.","Interest rate grid based on leverage: Term Benchmark loans range from SOFR+1.00% to +1.625%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363192,"accession_number":"0001628280-22-019768","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q2 record net sales $236.7M (+17% YoY), GAAP EPS $0.92, adj. EPS $1.07","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales $236.7M, up 17% YoY; GAAP EPS $0.92, adjusted EPS $1.07 (record).","Adjusted EBITDA $56.5M, up 12.6% YoY; all three segments posted sales growth.","Completed acquisition of Kappa (vitamin K2 manufacturer) on June 21, 2022; expands nutrition portfolio.","Entered new $550M revolving credit facility due 2027, replacing $500M facility due 2023.","Cash from operations $48.2M; net debt $357.4M, leverage ratio 1.8x."],"consensus_eps_estimate":null,"consensus_eps_actual":1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":465560000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382944,"accession_number":"0001140361-22-024070","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["2.01","5.07","7.01","9.01"],"status":"ready","headline":"Balchem closes $332.5M acquisition of Kappa Bioscience, financed via credit facility and cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price ~NOK 3.3B ($332.5M) includes assumption and repayment of NOK 303.5M ($30.6M) of Kappa debt.","Seller eligible for earn-out payment in 2024 of up to ~16% of NOK 3.175B based on growth targets.","Kappa is a leading science-based manufacturer of specialty vitamin K2 for human nutrition.","At Annual Meeting, shareholders elected three Class 1 directors, ratified RSM US LLP as auditor, and approved executive compensation on advisory basis.","Acquisition financed through Balchem's existing revolving credit facility and cash on hand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382943,"accession_number":"0001140361-22-023001","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Balchem to acquire Kappa Bioscience for $338M; accretive to EPS in 2022","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value of NOK 3.175B (~$338M); EV/EBITDA multiple of 18x on 2022 forecast.","Kappa's FY2022 forecast revenues ~NOK 500M (~$53M) with strong growth and margin profile.","Additional earn-out potential of 0% to 16% of enterprise value in 2024 based on performance.","Closing expected Q2 2022; financed via existing revolver and cash on hand.","Deal expected to be accretive to Balchem's adjusted EPS in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382942,"accession_number":"0001140361-22-022224","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Balchem General Counsel and Secretary Mark Stach to retire by Dec 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Stach notified Balchem of his intent to retire; will step down upon appointment of a successor.","Transition period: Stach will remain with the company until December 31, 2022.","No successor has been named yet; company says it will conduct a search.","Stach served as General Counsel and Secretary for the last five years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382941,"accession_number":"0001628280-22-011277","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q1 2022: Record sales $228.9M, GAAP EPS $0.89, adjusted EPS $1.03, all segments up double-digit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $228.9M (+23.3% YoY); GAAP net earnings $28.9M (+23.6% YoY); diluted GAAP EPS $0.89.","Adjusted EPS $1.03 (vs $0.87 YoY); adjusted EBITDA $53.6M (+17.2% YoY).","All three segments (Human Nutrition, Animal Nutrition, Specialty Products) delivered double-digit sales growth.","Cash from operations $7.0M; free cash flow $(2.8)M for the quarter.","Released 2021 Sustainability Report; targets 25% reduction in emissions and water usage by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":228867000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400765,"accession_number":"0001628280-22-003111","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem Q4 record sales $213M (+17.9% YoY); adj. EPS $0.85; dividend up 10.3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $213.1M (+17.9% YoY); GAAP EPS $0.76, adjusted EPS $0.85 (up from $0.83).","Full year net sales $799M (+13.6%); GAAP EPS $2.94 record, adjusted EPS $3.57.","Record Q4 adjusted EBITDA $45.6M (+4.7%); FY adjusted EBITDA $189.8M (+8.9%).","Increased quarterly dividend to $0.64/share (+10.3%), 12th consecutive year of double-digit growth.","Q4 ops cash $44.5M; free cash flow $124.4M FY; net debt reduced to $5.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":799023000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419751,"accession_number":"0001140361-21-042008","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Balchem declares $0.64/share dividend, a 10.3% annual increase","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.64 per share, payable Jan 21, 2022, to holders of record Dec 28, 2021.","Represents a 10.3% increase over last year's annual dividend.","Thirteenth consecutive annual dividend increase, reflecting confidence in long-term strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419750,"accession_number":"0001628280-21-020786","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2021-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem reports record Q3 2021 sales of $197.9M, net earnings $25.0M, EPS $0.77","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $197.9M, up 13% YoY; record sales in all three segments: Human Nutrition, Animal Nutrition, and Specialty Products.","GAAP EPS $0.77; adjusted EPS $0.92 vs $0.83 prior year; adjusted EBITDA $48.3M, up 9%.","Cash flow from operations $39.6M, free cash flow $31.1M, both up YoY.","Started new Metalosate production line in Marano, Italy to serve international customers.","Completed ERP consolidation to Microsoft Dynamics 365 on budget and on time."],"consensus_eps_estimate":null,"consensus_eps_actual":2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":585890000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437306,"accession_number":"0001628280-21-014976","cik":9326,"company_name":"BALCHEM CORP","ticker":"BCPC","form_type":"8-K","filed_at":"2021-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Balchem reports record Q2 sales of $202.4M, GAAP EPS $0.70, adjusted EPS $0.93, up 16.7% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 net sales $202.4M, up 16.7% YoY; all three segments set records.","GAAP net earnings $22.7M ($0.70 EPS); adjusted net earnings $30.4M ($0.93 EPS).","Adjusted EBITDA $50.1M, up 14.3% from $43.9M in prior year quarter.","Quarterly cash from ops $35.8M; free cash flow $28.4M; repaid $30M revolver debt.","Flood at Verona, MO plant caused $3.8M impact; plant now operational; insurance claim filed."],"consensus_eps_estimate":null,"consensus_eps_actual":1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":388021000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5170333375.520248,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}